Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have been diagnosed with chronic myeloid leukaemia (CML), a type of blood cancer
- People who have been taking a medication called ponatinib at a daily dose of 45mg, 30mg, or 15mg for more than 14 days
- People who have agreed to take part in the study by signing an informed consent form
Who may not be able to join:
- People under the age of 18
- People who have not agreed to take part in the study by signing an informed consent form
Additional note: Taking other medications alongside ponatinib does not prevent someone from joining this trial. However, the trial team will record all other medications being taken, including their doses and how long they have been used, as these may affect how ponatinib behaves in the body.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sara Galimberti, PhD, University of Pisa - Dept. Clinical and Experimental Medicine
Phone: +39 050 993111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ponatinib plasma concentrations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.